(CPB) Campbell’s - Ratings and Ratios
Soups, Sauces, Broths, Cookies, Crackers, Chips
Dividends
| Dividend Yield | 6.64% |
| Yield on Cost 5y | 4.79% |
| Yield CAGR 5y | 1.40% |
| Payout Consistency | 70.8% |
| Payout Ratio | 74.6% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 24.8% |
| Value at Risk 5%th | 40.0% |
| Relative Tail Risk | -2.16% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.44 |
| Alpha | -39.74 |
| CAGR/Max DD | -0.40 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.335 |
| Beta | 0.180 |
| Beta Downside | 0.159 |
| Drawdowns 3y | |
|---|---|
| Max DD | 43.22% |
| Mean DD | 21.80% |
| Median DD | 21.57% |
Description: CPB Campbell’s November 04, 2025
The Campbell’s Company (NYSE: CPB) manufactures and markets a broad portfolio of food and beverage brands across two segments-Meals & Beverages and Snacks-serving retail and food-service channels in the United States, Canada, and Latin America. The Meals & Beverages segment includes iconic items such as Campbell’s soups, Swanson broths, V8 juices, and Pacific Foods plant-based beverages, while the Snacks segment houses Pepperidge Farm cookies, Goldfish crackers, Kettle Brand chips, and Snyder’s pretzels, among others.
Key recent metrics: CPB reported FY 2023 net sales of roughly $5.7 billion, with the Snacks segment delivering a 4.5 % higher contribution margin than the Meals & Beverages segment, reflecting a strategic shift toward higher-margin, on-the-go products. Inflation-driven input-cost volatility and a consumer tilt toward healthier, plant-based options remain primary economic drivers for the business; CPB’s acquisition of Pacific Foods in 2020 positions it to capture growth in the “better-for-you” category, which the packaged-foods industry is seeing a 6-7 % CAGR in North America. Additionally, the company’s exposure to private-label competition in mass discounters adds execution risk to its pricing power.
If you want to explore CPB’s valuation sensitivities, cash-flow projections, and peer-group benchmarks in more depth, ValueRay’s analytics platform offers a convenient way to continue the research.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income (602.0m TTM) > 0 and > 6% of Revenue (6% = 615.2m TTM) |
| FCFTA 0.05 (>2.0%) and ΔFCFTA 0.43pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -6.57% (prev -14.38%; Δ 7.81pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.08 (>3.0%) and CFO 1.14b > Net Income 602.0m (YES >=105%, WARN >=100%) |
| Net Debt (7.08b) to EBITDA (1.57b) ratio: 4.50 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.77 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (299.0m) change vs 12m ago 0.34% (target <= -2.0% for YES) |
| Gross Margin 30.42% (prev 30.83%; Δ -0.41pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 68.06% (prev 63.25%; Δ 4.81pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 3.31 (EBITDA TTM 1.57b / Interest Expense TTM 345.0m) >= 6 (WARN >= 3) |
Altman Z'' 1.69
| (A) -0.05 = (Total Current Assets 2.23b - Total Current Liabilities 2.91b) / Total Assets 14.90b |
| (B) 0.32 = Retained Earnings (Balance) 4.69b / Total Assets 14.90b |
| (C) 0.08 = EBIT TTM 1.14b / Avg Total Assets 15.07b |
| (D) 0.43 = Book Value of Equity 4.69b / Total Liabilities 10.99b |
| Total Rating: 1.69 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 58.31
| 1. Piotroski 2.50pt |
| 2. FCF Yield 4.43% |
| 3. FCF Margin 6.99% |
| 4. Debt/Equity 1.85 |
| 5. Debt/Ebitda 4.50 |
| 6. ROIC - WACC (= 3.89)% |
| 7. RoE 15.51% |
| 8. Rev. Trend 52.81% |
| 9. EPS Trend -35.22% |
What is the price of CPB shares?
Over the past week, the price has changed by -3.67%, over one month by -1.44%, over three months by -8.99% and over the past year by -28.14%.
Is CPB a buy, sell or hold?
- Strong Buy: 4
- Buy: 2
- Hold: 12
- Sell: 3
- Strong Sell: 2
What are the forecasts/targets for the CPB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 34.4 | 17.1% |
| Analysts Target Price | 34.4 | 17.1% |
| ValueRay Target Price | 29 | -1.2% |
CPB Fundamental Data Overview December 03, 2025
P/E Trailing = 15.2189
P/E Forward = 12.3916
P/S = 0.8891
P/B = 2.3255
P/EG = 0.7555
Beta = -0.055
Revenue TTM = 10.25b USD
EBIT TTM = 1.14b USD
EBITDA TTM = 1.57b USD
Long Term Debt = 6.06b USD (from longTermDebt, last quarter)
Short Term Debt = 858.0m USD (from shortTermDebt, last quarter)
Debt = 7.21b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.08b USD (from netDebt column, last quarter)
Enterprise Value = 16.20b USD (9.12b + Debt 7.21b - CCE 132.0m)
Interest Coverage Ratio = 3.31 (Ebit TTM 1.14b / Interest Expense TTM 345.0m)
FCF Yield = 4.43% (FCF TTM 717.0m / Enterprise Value 16.20b)
FCF Margin = 6.99% (FCF TTM 717.0m / Revenue TTM 10.25b)
Net Margin = 5.87% (Net Income TTM 602.0m / Revenue TTM 10.25b)
Gross Margin = 30.42% ((Revenue TTM 10.25b - Cost of Revenue TTM 7.13b) / Revenue TTM)
Gross Margin QoQ = 30.37% (prev 29.41%)
Tobins Q-Ratio = 1.09 (Enterprise Value 16.20b / Total Assets 14.90b)
Interest Expense / Debt = 1.18% (Interest Expense 85.0m / Debt 7.21b)
Taxrate = 21.20% (39.0m / 184.0m)
NOPAT = 899.2m (EBIT 1.14b * (1 - 21.20%))
Current Ratio = 0.77 (Total Current Assets 2.23b / Total Current Liabilities 2.91b)
Debt / Equity = 1.85 (Debt 7.21b / totalStockholderEquity, last quarter 3.90b)
Debt / EBITDA = 4.50 (Net Debt 7.08b / EBITDA 1.57b)
Debt / FCF = 9.87 (Net Debt 7.08b / FCF TTM 717.0m)
Total Stockholder Equity = 3.88b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.04% (Net Income 602.0m / Total Assets 14.90b)
RoE = 15.51% (Net Income TTM 602.0m / Total Stockholder Equity 3.88b)
RoCE = 11.48% (EBIT 1.14b / Capital Employed (Equity 3.88b + L.T.Debt 6.06b))
RoIC = 8.03% (NOPAT 899.2m / Invested Capital 11.20b)
WACC = 4.14% (E(9.12b)/V(16.33b) * Re(6.68%) + D(7.21b)/V(16.33b) * Rd(1.18%) * (1-Tc(0.21)))
Discount Rate = 6.68% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF Debug] Terminal Value 77.66% ; FCFE base≈697.4m ; Y1≈668.9m ; Y5≈652.8m
Fair Price DCF = 39.11 (DCF Value 11.64b / Shares Outstanding 297.7m; 5y FCF grow -5.44% → 3.0% )
EPS Correlation: -35.22 | EPS CAGR: -46.78% | SUE: -4.0 | # QB: 0
Revenue Correlation: 52.81 | Revenue CAGR: 1.00% | SUE: -0.56 | # QB: 0
EPS next Quarter (2026-01-31): EPS=0.64 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=16
EPS current Year (2026-07-31): EPS=2.46 | Chg30d=-0.001 | Revisions Net=+2 | Growth EPS=-17.2% | Growth Revenue=-3.0%
EPS next Year (2027-07-31): EPS=2.67 | Chg30d=-0.001 | Revisions Net=+2 | Growth EPS=+8.6% | Growth Revenue=+1.3%
Additional Sources for CPB Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle